RO7790121A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor:

Hoffmann-La Roche

Code:

NCT06588855

Conditions

Moderately to Severely Active Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 16 - 70+

Healthy Volunteers: Not accepted

Interventions

Afimkibart

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-20. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-05.